Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Journey Medical (DERM) Research & Development (2021 - 2025)

Journey Medical's Research & Development history spans 5 years, with the latest figure at $154000.0 for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development fell 29.36% year-over-year to $154000.0, compared with a TTM value of $480000.0 through Dec 2025, down 95.13%, and an annual FY2025 reading of $480000.0, down 95.13% over the prior year.
  • Research & Development for Q4 2025 was $154000.0 at Journey Medical, down from $287000.0 in the prior quarter.
  • The five-year high for Research & Development was $7.9 million in Q1 2024, with the low at $29000.0 in Q2 2021.
  • Average Research & Development over 5 years is $1.8 million, with a median of $1.4 million recorded in 2022.
  • Year-over-year, Research & Development soared 8896.55% in 2022 and then plummeted 99.51% in 2025.
  • Tracing DERM's Research & Development over 5 years: stood at $2.0 million in 2021, then soared by 113.65% to $4.3 million in 2022, then crashed by 64.64% to $1.5 million in 2023, then plummeted by 85.51% to $218000.0 in 2024, then fell by 29.36% to $154000.0 in 2025.
  • Per Business Quant, the three most recent readings for DERM's Research & Development are $154000.0 (Q4 2025), $287000.0 (Q3 2025), and $39000.0 (Q1 2025).